Delta sleep-inducing peptide (DSIP) and Semax occupy different corners of the peptide research landscape. DSIP emerged from sleep physiology work in the late 1970s, when researchers isolated a nonapeptide from rabbit cerebral venous blood during thalamic stimulation. Semax, by contrast, is a synthetic ACTH fragment analogue developed in Russia and studied for cognitive effects. Pairing them raises a question that recurs across longevity and biohacking communities: do mechanisms align, or do they cancel out?
This article examines published research on DSIP, Semax, and related peptides like Thymalin, TB-500, MK-677, and GHK-Cu. It does not recommend personal use. Instead, it maps what the literature says about sleep architecture, neuroprotection, and recovery signaling. The goal is to separate documented interactions from speculative stacking.
The development of DSIP and Semax
DSIP was first described by Monnier and colleagues in 1977. The peptide sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Early experiments showed that infusing DSIP into rabbits increased slow-wave sleep. Later work in rats and humans produced mixed results. A 1984 review noted that DSIP effects depended heavily on baseline sleep state and route of administration (Schoenenberger 1984).
Semax has a different origin. It was synthesized at the Institute of Molecular Genetics in Moscow. The peptide is a modified fragment of adrenocorticotropic hormone, specifically ACTH(4-10), with a Pro-Gly-Pro tail added for stability. A 2010 review summarized Semax studies showing improved attention and memory in models of cerebral ischemia (Ashmarin et al. 2010).
Neither compound is approved as a drug in the United States or European Union. DSIP remains a research peptide. Semax is sold as a nootropic in some regions but lacks regulatory approval elsewhere.
Regulatory context for research peptides
DSIP and Semax fall into a gray zone. In the US, peptides sold for human consumption are generally unapproved new drugs. The FDA has issued warning letters to companies selling DSIP and Semax as dietary supplements. A 2021 warning letter cited claims that DSIP could treat insomnia and that Semax improved cognitive function. Those claims made the products unapproved drugs, not supplements.
In Russia, Semax has a different status. It is registered as a nasal spray for cognitive disorders. That approval does not transfer to other countries. Researchers outside Russia who want to study Semax must source it as a research chemical or through approved clinical trial channels.
Thymalin, a thymic peptide sometimes stacked with DSIP for immune support, has a similar profile. It was studied in Soviet-era clinical trials but never received Western regulatory approval. MK-677, a growth hormone secretagogue, is also unapproved for human use outside clinical trials. TB-500 and GHK-Cu are sold as research peptides or cosmetic ingredients, not as drugs.
Industry response to stacking demand
Vendors have noticed the interest in DSIP plus Semax. Some now sell pre-mixed vials or combination kits. Marketing copy often describes DSIP as a sleep aid and Semax as a daytime cognitive enhancer. The implication is that one can use DSIP at night and Semax in the morning. That framing is convenient but not supported by pharmacokinetic data.
A 2019 study measured DSIP half-life in human plasma at roughly 15 minutes after intravenous injection (Kastin et al. 2019). Intranasal Semax shows peak concentrations within 30 minutes and a half-life under an hour. The short half-lives mean that timing matters, but they also mean that any interaction window is brief.
Some suppliers now offer Semax in forms designed for sublingual or intranasal use. DSIP is usually sold as a lyophilized powder for subcutaneous injection. The mismatch in administration routes complicates stacking. A user would need two different delivery methods and two different timing schedules.
What practitioners are watching
Clinicians who work with peptides tend to watch three things: sleep architecture changes, cognitive test scores, and inflammatory markers. For DSIP, the most cited human data come from a 1981 trial in which DSIP infusion increased slow-wave sleep in some subjects but not others (Schneider-Helmert 1981). The effect was not dose-dependent in a simple way.
Semax research focuses on neuroprotection. A 2017 animal study found that Semax reduced infarct size after middle cerebral artery occlusion (Medvedeva et al. 2017). Another line of work examines Semax effects on brain-derived neurotrophic factor expression. Those findings are often extrapolated to healthy users, but the evidence base is thin.
Thymalin is sometimes added to DSIP stacks for immune modulation. A 2020 review of thymic peptides noted that Thymalin improved T-cell function in elderly patients with recurrent infections (Khavinson et al. 2020). Whether that effect synergizes with DSIP or Semax is unknown. TB-500 and GHK-Cu are often discussed for tissue repair, but their interaction with sleep peptides has not been studied.
Likely trajectory for DSIP and Semax research
The most probable path forward is more preclinical work on combination effects. A 2022 review of peptide combinations for neuroprotection called for systematic dose-response studies before human trials (Gudasheva et al. 2022). That review did not specifically address DSIP plus Semax, but the principle applies.
Another possibility is that DSIP research stalls. The peptide has been studied for over 40 years without a clear clinical indication. Funding for sleep peptide research has shifted toward orexin receptor antagonists and other targets. Semax, by contrast, has a larger Russian-language literature and ongoing work on delivery systems.
For now, the stack remains a hypothesis. The mechanisms are plausible: DSIP may modulate GABAergic tone, while Semax may increase BDNF and improve cerebral blood flow. But plausibility is not evidence. The current literature does not contain a single study administering both peptides together in humans or animals.
Information here reflects published findings at the time of writing and may be superseded by newer research.